Question 1 · Hard
A 45-year-old man in a tribal block of Jharkhand has had cough for 3 weeks and weight loss. At the designated microscopy centre, the medical officer explains his test to the patient and an intern. Consider four statements: 1. CBNAAT detects M. tuberculosis and rifampicin resistance in about two hours. 2. A positive CBNAAT result shows that the bacilli are alive, so it is used to monitor response to treatment. 3. Truenat, an Indian chip-based real-time PCR, is also used under NTEP for diagnosis. 4. Rifampicin resistance on CBNAAT is used as a marker of MDR/RR-TB. Which statements are correct?
- A1 and 3 only
- B2, 3 and 4 only
- C1, 3 and 4 only
- D1 and 2 only
Show answerHide answer
Answer: C · 1, 3 and 4 only
Statements 1, 3 and 4 are correct. CBNAAT is a cartridge-based real-time PCR that gives a result for M. tuberculosis and rifampicin resistance in about two hours, and Truenat, a portable chip-based real-time PCR developed in India, is also used under NTEP. Rifampicin resistance is taken as a marker of MDR/RR-TB because it rarely occurs alone, and the specimen then goes for line probe assays and culture-based testing. Statement 2 is false: PCR detects DNA, including DNA from dead bacilli, so it can stay positive during successful treatment; follow-up uses smear microscopy and culture.
- A: Leaves out statement 4; rifampicin resistance is the NTEP marker of MDR/RR-TB.
- B: Includes statement 2; NAAT cannot show whether bacilli are viable.
- D: Includes statement 2; DNA from dead bacilli makes NAAT unsuitable for follow-up.